Table 5.
Prevalence of Pfmdr1 alleles and haplotypes in day 0 (pre-treatment) and day of recurrent infection samples in the artemether-lumefantrine arm, 2018–2019 therapeutic efficacy monitoring
| aPfmdr1 codon | Day 0 | Day of recurrent infection |
|---|---|---|
| N86 | 128 (100%) | 127 (100%) |
| 86N/Y (N = 255) | 0 (0%) | 0 (0%) |
| 86Y | 0 (0%) | 0 (0%) |
| Y184 | 48 (38%) | 38 (32%) |
| Y184Y/F (N = 246) | 37 (29%) | 38 (32%) |
| 184F | 43 (34%) | 42 (36%) |
| S1034 | 126 (100%) | 111 (100%) |
| 1034S/C (N = 237) | 0 (0%) | 0 (0%) |
| 1034C | 0 (0%) | 0 (0%) |
| N1042 | 127 (100%) | 111 (100%) |
| 1042N/D (N = 238) | 0 (0%) | 0 (0%) |
| 104D | 0 (0%) | 0 (0%) |
| D1246 | 116 (91%) | 107(96%) |
| 1246D/Y (N = 239) | 5 (4%) | 2(2%) |
| 1246Y | 6 (5%) | 3 (3%) |
| Pfmdr1 haplotypesb | n = 127c | n = 110c |
| NFD | 78 (61%) | 76 (69%) |
| NYD | 79 (62%) | 68 (62%) |
| YFD | 0 | 0 |
| YYD | 0 | 0 |
| YYY | 0 | 0 |
| NYY | 9 (7%) | 4 (4%) |
| YFY | 0 | 0 |
| NFY | 6 (5%) | 3 (3%) |
aData presented are for participants with either later clinical failure or late parasitological failure
bEach possible haplotype constructed from the mixed infections (wildtype and mutant) was reported. Haplotype percentages exceed a sum of 100% because all possible haplotypes from mixed infections (both wild type and mutants) were included in the construction of haplotypes
cN includes samples for which data were available for all three markers